Navigation Links
Poniard Pharmaceuticals to Present at Needham & Company's Cancer Therapeutics: Today & Tomorrow Conference
Date:3/19/2009

SOUTH SAN FRANCISCO, Calif., March 19 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that Jerry McMahon, Ph.D., chairman and CEO, will present at the Needham & Company Cancer Therapeutics: Today & Tomorrow Conference on Thursday, March 26, at 10 a.m. Eastern Time in New York.

Dr. McMahon will provide a corporate overview, including a discussion of the clinical development program for picoplatin, the Company's lead product candidate.

A live audio webcast of the presentation will be available for 10 business days on the "Events" page of the "News & Events" section of the Company's website at http://www.poniard.com.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration-resistant (hormone-refractory) prostate cancers. The Company also is conducting a clinical trial of oral picoplatin in solid tumors. For additional information please visit http://www.poniard.com.

(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.

For Further Information:


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Poniard Pharmaceuticals Receives Going Concern Qualification
2. Poniard Pharmaceuticals Announces Appointment of Greg Weaver as Chief Financial Officer
3. Poniard Pharmaceuticals Provides 2009 Clinical Data Goals for Picoplatin
4. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
5. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
6. Poniard Pharmaceuticals Announces Upcoming Conference Participation
7. Statement by Teva Pharmaceuticals on Eshoo-Barton Bill
8. China Yongxin Pharmaceuticals Inc. Launches Electronic Diagnosis System in its Changchun Drugstores
9. Transcept Pharmaceuticals to Report Fourth Quarter 2008 Results
10. Meditor Pharmaceuticals (North American) Ltd. announces the closing of a merger agreement with American Medical Technologies, Inc.
11. Gamma Pharmaceuticals Accepts PO From Leading St. Louis Missouri Distributor. Order Valued up to $850,000 Retail Market Value
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... They are musicians and librarians, fashion ... brothers and fathers, from New England and around the nation. What do they have ... brought together in a beautiful and compelling new photographic exhibit debuting Friday, December 9 ...
(Date:12/7/2016)... TX (PRWEB) , ... December 07, 2016 , ... ... offering insurance and financial planning services to families and business owners in the ... funds on behalf of the Dallas Fallen Officer Foundation. , Established in 2009 ...
(Date:12/7/2016)... ... 07, 2016 , ... Sharon Kleyne, host of the nationally syndicated radio program, ... Voice of America, declared on her radio program in November 2016 the need to ... these bullies attack leaders in corporate America, they are trying to take advantage of ...
(Date:12/7/2016)... TX (PRWEB) , ... December 07, 2016 , ... ... 2016 Top 20 Marketing Campaign Winner in the Folio: Marketing Awards competition. Live ... recognize the year’s best in pioneering, inventive, and ultimately successful projects undertaken by ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... (IFW) Program at Reproductive Medicine Associates of Connecticut (RMACT). McLaughlin brings nearly 20 ... of three acupuncturists to help patients realize their family building goals. Acupuncture ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... , Dec. 7,2016  Based on ... delivery industry, Frost & Sullivan recognizes Nemaura ... & Sullivan Award for Enabling Technology Leadership. ... the loopholes in traditional drug delivery technologies, ... liquid microneedle-based drug delivery technologies, Memspatch and ...
(Date:12/7/2016)... , December 7, 2016 According ... Research titled , Global Market Study on Multiplex Detection Immunoassay: ... , the global multiplex detection immunoassay market is expected to ... 2016-2024. ... ,      ...
(Date:12/6/2016)... Mass. , Dec. 6, 2016  Alopexx Oncology, ... DI-Leu16-IL2, a recombinant antibody fusion protein (immunocytokine) composed of ... recognizes the same target on B cells as Rituxan ... cytokine components but is also involved in tumor targeting, ... anti-cancer vaccine effect. The results of the study (abstract ...
Breaking Medicine Technology: